This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.

收市小结 (2020-3-17)

By:

Sales Trader, International Business Division

市场概况

周二,今日两市小幅高开后杀跌,创业板指盘中一度跌逾3%,随后见底强劲反弹,但个股仍是跌多涨少格局,从盘面攻击主线来看,光刻胶、特高压成市场最大风口,口罩概念股、农业、白酒等板块领跌,近期指数波动较大,短期震荡难免。截至收盘,沪指跌0.34%报2779点,深成指跌0.49%报10202点,创业板指涨0.36%报1917点。

消息面

  1. 泸州老窖公告,为打造区位集中的现代化生产基地,公司决定由全资子公司酿酒公司按照评估值以自有资金约2.28亿元(含交易增值税)向公司控股股东老窖集团全资子公司嘉信集团购买土地及配套构筑物用于基酒存储。(财联社)
  2. 国务院联防联控机制新闻发布会上表示法匹拉韦治疗新冠肺炎的“临床疗效很好”,且已实现量产,建议尽快纳入诊疗方案。《科创板日报》记者查询国家药品监督管理局公开信息发现,海正药业已于2020年2月15日取得法匹拉韦上市许可,系国内唯一一家。(财联社)
  3. 恒瑞医药公告,公司及子公司公司近日收到国家药监局核准签发的《临床试验通知书》,并将于近期开展临床试验。药品名称:SHR2150注射液 ,SHR2150注射液拟用于晚期恶性肿瘤的治疗。其它同类药物尚处于临床开发阶段,国内外尚无同类产品获批上市,亦无相关销售数据。截至目前,该产品项目已投入研发费用约为4038万元。(财联社)

交易点评

当前A股总体向好的趋势并未改变,事件影响下短期节奏或有变化。

资金流向

行业板块资金流向方面,资金流入居前的板块是电子信息、发电设备和电子器件行业,资金流出居前的板块是医疗器械、纺织和玻璃行业。

沪股通及深股通方面,沪股通资金净流出50.42亿元,当日余额570.42亿元;深股通资金净流出21.00亿元,当日余额541.00亿元。

截至收盘

开盘 收盘 涨跌幅% 成交额(亿元)
沪指 2796.28 2779.64 -0.34 3230.13
深成指 9125.27 10202.75 -0.49 4950.73
沪深300 3739.78 3709.68 -0.49 2508.24
创业板 1941.20 1917.70 0.36 1671.97
Disclosure: Interactive Brokers

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Guosen Securities Co., Ltd and is being posted with permission from Guosen Securities Co., Ltd. The views expressed in this material are solely those of the author and/or Guosen Securities Co., Ltd and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Disclosure: Chinese Translation

这篇文章已被翻译成中文。如英文版本和中文版本之间有任何不一致,以英文版本为准。该文章中的分析仅为提供信息,不是也不应该被视为推销或招揽购买任何证券。文章中讨论的一般市场活动、行业或领域趋势、或其它基于广泛的经济或政治条件的内容,不应被解释为研究结果或投资建议。讨论中提及包括的特定证券、商品、货币、或其它产品均不构成IB推荐购买,出售或持有此类投资的建议。本材料不是也不意图针对个别客户的特定财务条件、投资目标或要求。在根据本材料采取行动之前,您应该考虑是否适合您的具体情况,并在必要时寻求专业建议。

盈透交易员睿智中提供的内容(包括文章和评论)仅作为资讯用途。发布的内容并不代表盈透证券建议您或您的客户联系独立顾问或对冲基金以期获取其服务或投资其产品,也不代表建议您联系在盈透交易员睿智发布文章或向顾问、对冲基金投资的相关人士。在盈透交易员睿智中发布文章的顾问、对冲基金或其他分析师均独立于盈透证券,盈透证券不会对这些顾问、对冲基金或其他人士的过往或将来表现,或其提供的信息之准确性做出任何声明或担保。盈透证券不会进行“适宜性评估”来确保顾问、对冲基金或其他参与方的交易适合于您。

发布内容中提及的证券或其他金融产品并非适合所有投资者。发布的内容并未从您的投资目标、财务状况或需求出发,并不旨在向您推荐任何证券、金融产品或策略。过往业绩并不代表将来表现,如有需要,请咨询相关人士获取专业的建议。

盈透或其分支机构的雇员所发布的任何信息均基于公认的真实可信的信息。然而,盈透或其分支机构无法保证信息的完整性、准确性和适当性。盈透不对任何金融产品其过去或将来的表现作出任何声明或担保。交易员睿智中发布的文章并不代表盈透认为任何特定金融产品或交易策略适合您。

trading top